J. Guigay

Institut Gustave Roussy — France

Medicine · Health Sciences

47h-index13.9kcitations347works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Head and Neck Cancer Studies(140), Cancer Immunotherapy and Biomarkers(78), Lung Cancer Treatments and Mutations(76), Lung Cancer Research Studies(55), Cancer Diagnosis and Treatment(45)

Publications347 total

1426P OSKAR: Real-world (RW) use of pembrolizumab in patients (pts) with unresectable recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in France: A prospective non-interventional multicentric study linked to the French National Health Data System (SNDS)
Annals of Oncology·2025
Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Value in Health·2025
Personalized biomarker-based treatment strategy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the biomarker-driven cohorts of the EORTC-HNCG-1559 trial (UPSTREAM).
Journal of Clinical Oncology·2025
Hypofractionated Split-Course Versus Standard Radiotherapy in Frail Elderly Patients with Head and Neck Squamous-Cell Carcinoma (ELAN-RT): A Multicenter, Open-Label, Randomized, Non-Inferiority GORTEC Trial
SSRN Electronic Journal·2025· 1 citedOpen Access
Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma
CPT Pharmacometrics & Systems Pharmacology·2024· 2 citedOpen Access
854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial
Annals of Oncology·2024· 16 cited
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial
The Lancet Healthy Longevity·2024· 8 citedOpen Access
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial
The Lancet Healthy Longevity·2024· 10 citedOpen Access
Tumor kinetics modeling outperforms best overall response for prediction of survival in head and neck squamous cell carcinoma
SPIRE - Sciences Po Institutional REpository·2024Open Access
Cetuximab Every 2 Weeks Versus Standard Weekly Dosing Administration Schedule
Future Oncology·2023· 7 citedOpen Access
938P Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Annals of Oncology·2023Open Access
NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08)
BMJ Oncology·2023· 9 citedOpen Access
Supplementary Figure 2 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023Open Access
Supplementary Table 6 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023Open Access
Supplementary Data from Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
2023Open Access
Supplementary Data from Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
2023· 1 citedOpen Access
Supplementary Table 5 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023Open Access
Supplementary Figure 2 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023Open Access
Supplementary Figure 1 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023Open Access
Supplementary Table 3 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023Open Access
page 1 of 18Next →

Frequent Co-authors

Jérôme Fayette(17), Caroline Even(15), Lisa Licitra(14), Robert I. Haddad(11), Makoto Tahara(11), Jean Bourhis(10), Robert L. Ferris(9), George R. Blumenschein(9), Kevin J. Harrington(9), Maura L. Gillison(9), A. Dimitrios Colevas(8), Everett E. Vokes(8), Nabil F. Saba(8), Stefan Kasper(7), Francis P. Worden(7), Naomi Kiyota(7), Mark Lynch(7), Didier Cupissol(7), Esma Saâda-Bouzid(6), Éric Baudin(6)